{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:17:06Z","timestamp":1780341426607,"version":"3.54.1"},"reference-count":38,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We prospectively studied clofarabine-fludarabine-busulfan (CloFluBu)-conditioning in allogeneic hematopoietic cell therapy (HCT) for lymphoid and myeloid malignancies and hypothesized that CloFluBu provides a less toxic alternative to conventional conditioning regimens, with adequate antileukemic activity. All patients receiving their first HCT, from 2011-2019, were included and received CloFluBu. The primary endpoint was event-free survival (EFS). Secondary endpoints were overall survival (OS), graft-versus-host disease (GvHD)-relapse-free survival (GRFS), treatment-related mortality (TRM), cumulative incidence of relapse (CIR), acute and chronic GvHD (aGvHD and cGvHD), and veno-occlusive disease (VOD). Cox proportional hazard and Fine and Gray competing-risk models were used for data analysis. One hundred fifty-five children were included: 60\u00a0acute lymphoid leukemia (ALL), 69 acute myeloid leukemia (AML), and 26 other malignancies (mostly MDS-EB). The median age was 9.7 (0.5 to 18.6) years. Estimated 2-year EFS was 72.0% \u00b1 6.0 in ALL patients, and 62.4% \u00b1 6.0 in AML patients. TRM in\u00a0the\u00a0whole cohort was 11.0% \u00b1 2.6, incidence of aGvHD 3 to 4 at 6 months was 12.3%\u00a0\u00b1 2.7, extensive cGvHD at 2 years was 6.4% \u00b1 2.1. Minimal residual disease-positivity prior to HCT was associated with higher CIR, both in ALL and AML. CloFluBu showed limited toxicity and encouraging EFS. CloFluBu is a potentially less toxic alternative to conventional conditioning regimens. Randomized prospective studies are needed.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005224","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T23:01:34Z","timestamp":1637017294000},"page":"1719-1730","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an\u00a0effective, low toxicity, TBI-free conditioning regimen"],"prefix":"10.1182","volume":"6","author":[{"given":"A. Birgitta","family":"Versluijs","sequence":"first","affiliation":[{"name":"Department of Pediatric Blood and Marrow Transplantation, Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"},{"name":"Department of Pediatric Blood and Marrow Transplantation, University Medical Center Utrecht, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coco C. H.","family":"de Koning","sequence":"additional","affiliation":[{"name":"Laboratory for Translational Immunology, University Medical Center, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan C.","family":"Lankester","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Willem Alexander Children\u2019s Hospital, Leiden University Medical Center, Leiden, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3406-817X","authenticated-orcid":false,"given":"Stefan","family":"Nierkens","sequence":"additional","affiliation":[{"name":"Laboratory for Translational Immunology, University Medical Center, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter J.","family":"Kollen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Blood and Marrow Transplantation, Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"},{"name":"Department of Pediatrics, Willem Alexander Children\u2019s Hospital, Leiden University Medical Center, Leiden, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorine","family":"Bresters","sequence":"additional","affiliation":[{"name":"Department of Pediatric Blood and Marrow Transplantation, Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"},{"name":"Department of Pediatrics, Willem Alexander Children\u2019s Hospital, Leiden University Medical Center, Leiden, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Lindemans","sequence":"additional","affiliation":[{"name":"Department of Pediatric Blood and Marrow Transplantation, Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"},{"name":"Department of Pediatric Blood and Marrow Transplantation, University Medical Center Utrecht, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-6952","authenticated-orcid":false,"given":"Jaap Jan","family":"Boelens","sequence":"additional","affiliation":[{"name":"Department of Pediatric Blood and Marrow Transplantation, Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"},{"name":"Department of Pediatric Blood and Marrow Transplantation, University Medical Center Utrecht, Utrecht, The Netherlands;"},{"name":"Laboratory for Translational Immunology, University Medical Center, Utrecht, The Netherlands;"},{"name":"Stem Cell Transplantation and Cellular Therapy, Memorial Sloan-Kettering, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bierings","sequence":"additional","affiliation":[{"name":"Department of Pediatric Blood and Marrow Transplantation, Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, The Netherlands;"},{"name":"Department of Pediatric Blood and Marrow Transplantation, University Medical Center Utrecht, Utrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"issue":"4","key":"2022031415283139900_B1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters","year":"2021","journal-title":"J Clin Oncol."},{"issue":"2","key":"2022031415283139900_B2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/08880018.2019.1591549","article-title":"The impact of severe late-effects after 12\u2009Gy fractionated total body irradiation and allogeneic stem cell transplantation for childhood leukemia (1988-2010)","volume":"36","author":"Freycon","year":"2019","journal-title":"Pediatr Hematol Oncol."},{"issue":"1","key":"2022031415283139900_B3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijrobp.2007.05.035","article-title":"Long-term outcome after static intensity-modulated total body radiotherapy using compensators stratified by pediatric and adult cohorts","volume":"70","author":"Schneider","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"9","key":"2022031415283139900_B4","first-page":"4859","article-title":"Treatment complications and long-term outcomes of total body irradiation in patients with acute lymphoblastic leukemia: a single institute experience","volume":"36","author":"De Felice","year":"2016"},{"key":"2022031415283139900_B5","first-page":"e11","author":"Hill","year":"2016"},{"issue":"6","key":"2022031415283139900_B6","first-page":"477","article-title":"Allogeneic bone marrow transplantation using unrelated donors: a pilot study of the Canadian Bone Marrow Transplant Group","volume":"8","author":"Phillips","year":"1991","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"2022031415283139900_B7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/bmt.2014.246","article-title":"Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002\/01 study","volume":"50","author":"Locatelli","year":"2015","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"2022031415283139900_B8","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41375-019-0584-8","article-title":"Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial","volume":"34","author":"Sauer","year":"2020","journal-title":"Leukemia."},{"issue":"6","key":"2022031415283139900_B9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2010.09.022","article-title":"Clofarabine \u00b1 fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS","volume":"17","author":"Andersson","year":"2011","journal-title":"Biol Blood Marrow Transplant."},{"issue":"2","key":"2022031415283139900_B10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bcp.2010.09.027","article-title":"The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling","volume":"81","author":"Valdez","year":"2011","journal-title":"Biochem Pharmacol."},{"issue":"10","key":"2022031415283139900_B11","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.bbmt.2016.06.023","article-title":"Long-term outcomes after treatment with clofarabine\u2009\u00b1\u2009fludarabine with once-daily intravenous busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and myelodysplastic syndrome","volume":"22","author":"Alatrash","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2022031415283139900_B12","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41409-020-01201-w","article-title":"Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens","volume":"56","author":"Versluys","year":"2021","journal-title":"Bone Marrow Transplant."},{"issue":"22","key":"2022031415283139900_B13","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","article-title":"Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: Study ALL10 from the Dutch Childhood Oncology Group","volume":"34","author":"Pieters","year":"2016","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022031415283139900_B14","doi-asserted-by":"crossref","first-page":"e27605","DOI":"10.1002\/pbc.27605","article-title":"Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: results from protocol DB AML-01","volume":"66","author":"De Moerloose","year":"2019","journal-title":"Pediatr Blood Cancer."},{"issue":"5","key":"2022031415283139900_B15","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.2012.43.7384","article-title":"Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group","volume":"31","author":"Kaspers","year":"2013","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022031415283139900_B16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/11598180-000000000-00000","article-title":"Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing","volume":"51","author":"Bartelink","year":"2012","journal-title":"Clin Pharmacokinet."},{"issue":"3","key":"2022031415283139900_B17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbmt.2013.11.027","article-title":"Fludarabine and exposure-targeted busulfan compares favorably with busulfan\/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity","volume":"20","author":"Bartelink","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"issue":"3","key":"2022031415283139900_B18","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.bbmt.2019.12.577","article-title":"Prospective open-label phase II trial of individualized anti-thymocyte globulin for improved T-cell reconstitution after pediatric allogeneic hematopoietic cell transplantation: The Parachute-Study","volume":"26","author":"Admiraal","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"2022031415283139900_B19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation."},{"issue":"2","key":"2022031415283139900_B20","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med."},{"issue":"1","key":"2022031415283139900_B21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","article-title":"Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors","volume":"4","author":"McDonald","year":"1984","journal-title":"Hepatology."},{"issue":"11","key":"2022031415283139900_B22","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.bbmt.2019.07.011","article-title":"Transplantation in children and adolescents with acute lymphoblastic leukemia from a matched donor versus an HLA-identical sibling: is the outcome comparable? Results from the International BFM ALL SCT 2007 Study","volume":"25","author":"Balduzzi","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2022031415283139900_B23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/sj.bmt.1704198","article-title":"Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study","volume":"32","author":"Bunin","year":"2003","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"2022031415283139900_B24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2012-02-409813","article-title":"Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia","volume":"120","author":"Leung","year":"2012","journal-title":"Blood."},{"issue":"21","key":"2022031415283139900_B25","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/bloodadvances.2019000449","article-title":"More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling","volume":"3","author":"Bader","year":"2019","journal-title":"Blood Adv."},{"key":"2022031415283139900_B26","first-page":"3","author":"Taraseviciute","year":"2019"},{"issue":"6","key":"2022031415283139900_B27","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bbmt.2011.10.031","article-title":"Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia","volume":"18","author":"Majhail","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"issue":"8","key":"2022031415283139900_B28","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and Trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D\u2019Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"5","key":"2022031415283139900_B29","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica."},{"issue":"2","key":"2022031415283139900_B30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/blood-2011-08-363291","article-title":"Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia","volume":"119","author":"Buccisano","year":"2012","journal-title":"Blood."},{"issue":"4","key":"2022031415283139900_B31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022031415283139900_B32","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood."},{"key":"2022031415283139900_B33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-140778","article-title":"Expanded comorbidity definitions improve applicability of the hematopoietic stem cell transplantation-comorbidity index for children, adolescents, and young adults with hematologic malignancies undergoing allogeneic stem cell transplantation","volume":"136","author":"Friend","year":"2020","journal-title":"Blood."},{"issue":"14","key":"2022031415283139900_B34","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/bloodadvances.2018029421","article-title":"Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes","volume":"3","author":"Langenhorst","year":"2019","journal-title":"Blood Adv."},{"issue":"3","key":"2022031415283139900_B35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbmt.2014.11.674","article-title":"Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab","volume":"21","author":"Willemsen","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"5","key":"2022031415283139900_B36","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","article-title":"Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis","volume":"2","author":"Admiraal","year":"2015","journal-title":"Lancet Haematol."},{"issue":"23","key":"2022031415283139900_B37","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2016-06-721936","article-title":"Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation","volume":"128","author":"Admiraal","year":"2016","journal-title":"Blood."},{"issue":"2","key":"2022031415283139900_B38","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/bmt.2017.161","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation","volume":"53","author":"Corbacioglu","year":"2018","journal-title":"Bone Marrow Transplant."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/6\/1719\/1880827\/advancesadv2021005224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/6\/1719\/1880827\/advancesadv2021005224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T15:29:04Z","timestamp":1647271744000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/6\/1719\/477973\/Clofarabine-fludarabine-busulfan-in-HCT-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,3,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005224","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]}}}